Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.53 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.53 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | CCR3 | P51677 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4205936 | 0.91 | CCR3 (0.64) | MCHR1CCR3 | |
| SCHEMBL4196888 | 0.89 | SIGMAR1 (0.62) | SIGMAR1NPC1RAB9ASMN1; SMN2MCHR1 | |
| SCHEMBL4201490 | 0.80 | CCR3 (0.66) | SIGMAR1MCHR1CCR3 | |
| SCHEMBL4207761 | 0.76 | RAB9A (0.54) | NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL5315300 | 0.75 | KDM4E (0.65) | SIGMAR1SMN1; SMN2KDM4E | |
| SCHEMBL64445 | 0.75 | KDM4E (0.68) | SMN1; SMN2KDM4E | |
| SCHEMBL25013994 | 0.74 | KDM4E (0.64) | SMN1; SMN2KDM4E | |
| SCHEMBL4207869 | 0.74 | SIGMAR1 (0.52) | SIGMAR1SMN1; SMN2MCHR1CCR3KDM4E | |
| SCHEMBL15745866 | 0.74 | MEN1 (0.60) | SIGMAR1SMN1; SMN2MCHR1SLC6A12TMEM97 | |
| SCHEMBL12011091 | 0.73 | KDM4E (0.57) | SIGMAR1MCHR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023733-A1 | Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023733-A1 | Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them | CCR3, CCR1, CCR5 | SIGMAR1 1718/4885NPC1 414/4885RAB9A 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.